TL1A, a critical marker in various autoimmune and inflammatory diseases, poses challenges for traditional immunoassay methods. This insightful webinar features industry experts discussing the advantages of high-resolution mass spectrometry (HRMS) in the LC-MS bioanalysis of biomarkers, with further insight from a TL1A assay case study.
Webinar highlights include:
- The establishment and use of a TL1A LC-MS method with practical adaption to biomarker measurements.
- Insights into the versatility of HRMS for biomarker analysis.
- How ‘context of use’ principles, combined with regulated bioanalytical guidance can provide practical solutions for drug development research.
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Combining immuno-affinity with liquid chromatography-mass spectrometry (LC-MS)
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
